BioNTech Bags Bargain With Neon Buy
Expands Cell Therapy Pipeline
Executive Summary
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.
You may also be interested in...
Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery
The Bill & Melinda Gates Foundation has invested $55m in an infectious disease collaboration with Germany’s BioNTech that could reach up to $100m in total funding.
BioNTech Fills Coffers With Extra $325m Via Series B Financing
Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.
Need a specific report? 1000+ reports available
Buy Reports